ArticleCancer immunology, immunotherapy : CII2006
Antitumor effects of a xenogeneic survivin bone marrow derived dendritic cell vaccine against murine GL261 gliomas.
Article in Cancer immunology, immunotherapy : CII, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 54 citations in OpenAlex.
- Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma.Cancer immunology, immunotherapy : CII · 2016Trial
- Translational Models for Glioblastoma: Revolutionizing Drug Development and Personalized Medicine through Clinical Insights.Theranostics · 2026Review
- Promising Cancer Vaccine for Glioblastoma Therapy: A Focus on mRNA Vaccine.Cancer medicine · 2025Review
- Single-nucleus RNA sequencing reveals a preclinical model for the most common subtype of glioblastoma.Communications biology · 2025Article
- Revolutionizing Glioblastoma Treatment: A Comprehensive Overview of Modern Therapeutic Approaches.International journal of molecular sciences · 2024Review
- Review
- 3D bioprinting of an implantable xeno-free vascularized human skin graft.Bioengineering & translational medicine · 2023Article
- Development of immunotherapy for high-grade gliomas: Overcoming the immunosuppressive tumor microenvironment.Frontiers in medicine · 2022Review
- Review
- Dendritic Cell Vaccination of Glioblastoma: Road to Success or Dead End.Frontiers in immunology · 2021Review
- High Therapeutic Efficacy of a New Survivin LSP-Cancer Vaccine Containing CD4Frontiers in oncology · 2018Article
- Bioluminescence and MR Imaging of the Safety and Efficacy of Vascular Disruption in Gliomas.Molecular imaging and biology · 2016Article
- Novel vaccines for glioblastoma: clinical update and perspective.Immunotherapy · 2016Review
- Overview of current immunotherapeutic strategies for glioma.Immunotherapy · 2015Review
- Survivin transcript variant 2 drives angiogenesis and malignant progression in proneural gliomas.Neuro-oncology · 2014Article
- Immunocompetent murine models for the study of glioblastoma immunotherapy.Journal of translational medicine · 2014Review
- Survivin as a potential mediator to support autoreactive cell survival in myasthenia gravis: a human and animal model study.PloS one · 2014Article
- In vitro enhancement of dendritic cell-mediated anti-glioma immune response by graphene oxide.Nanoscale research letters · 2014Article
- Natural HLA class I ligands from glioblastoma: extending the options for immunotherapy.Journal of neuro-oncology · 2013Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Survivin is a member of the inhibitor of apoptosis protein family. Gliomas and many other tumors express survivin at high levels; whereas, normal fully differentiated cells generally do not. Therefore, survivin represents a tumor-specific target for cancer vaccine therapy. It has been shown that it is possible to produce a MHC-I-restricted cellular immunologic response to survivin vaccines. To study differences in immunogenicity between murine and human survivin proteins, we vaccinated C57BL/6 mice with bone marrow dendritic cells (BMDC) transfected with expression vectors containing the murine and human survivin genes. Mice vaccinated with BMDCs expressing a truncated human survivin protein developed cytotoxic T lymphocyte to subcutaneous GL261 glioma cells and exhibited prolonged tumor-free survival compared to mice vaccinated with BMDCs transfected with vector alone (P<0.01). While mice challenged with intracerebral GL261 cells had increased survival, no cures were observed. In contrast, vaccinated mice that fully resisted subcutaneous tumor challenge were rendered resistant to intracerebral GL261 re-challenge. BMDCs transfected with the full-length human survivin molecule were significantly more effective at prolonging survival than BMDCs expressing the full-length murine survivin gene (P=0.0175). Therefore, xenogeneic differences between human and murine sequences might be exploited to develop more immunogenic tumor vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.